摘要
目的观察瑞舒伐他汀钙对高脂血症患者血脂、血管内皮生长因子（VEGF）、一氧化氮（NO）、肿瘤坏死因子（TNF）-α、白细胞介素（IL）-1的影响。方法将127例高脂血症患者按随机数字表法分为两组，研究组72例，给予瑞舒伐他汀钙10mg和肠溶阿司匹林100mg口服，每日1次，共8周；对照组55例，仅给予肠溶阿司匹林100mg口服，每日1次，共8周。测定两组患者治疗前后血脂水平[总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL—C）]及血清VEGF、NO、TNF-α、IL-1水平的变化。结果治疗前丽组TC、TG、LDL-C、HDL-C、VEGF、NO、TNF-α、IL-1比较差异均无统计学意义（P〉0．05）；治疗后，研究组TC、TG、LDL-C、TNF-α、IL-1明显低于对照组[（4．410±0．688）mmol／L比（6．491±0．744）mmol／L、（1．762±0．834）mmol／L比（2．632±0．792）mmol／L、（2．256±0．347）mmol／L比（4．544±0．493）mmol／L、（41．14±5．41）ng／L比[71．34±6．76）ng／L、（0．22±0．18）μg/L比（0．42±0．23）μg／L]，HDL-C、VEGF、NO明显高于对照组[（1．807±0．730）mmol／L比（1．432±0．514）mmol／L、（564．86±120．02）ng／L比（451．23±100．72）ng／L、（42．39±6．71）μmol／L比（33．65±6．24）μmol／L]，差异均有统计学意义（P〈0．05）。两组患者治疗过程中均未见明显不良反应。结论瑞舒伐他汀钙能明显降低高脂血症患者血脂，升高VEGF、NO，降低TNF-α、IL-1，显著改善血管内皮功能。
Objeαive To observe the effeα of rosuvastatin calcium on lipid,vascular endothelial growth faαor （VEGF）,nitric oxide （NO）,tumor necrosis faαor （TNF）-α and interleukin （IL）-I inhyperlipidemia patients. Methods One hundred and twenty-seven hyperlipidemia patients were randomly divided into two groups. Patients in the study group included 72 patients which were given rosuvastatin calcium 10 mg and enteric-coated aspirin 100 mg, orally, once a day for 8 weeks. The control group included 55 patients which were only given enteric-coated aspirin 100mg,orally, once a day for 8 weeks. The change of lipid, VEGF, NO, TNF-α and IL-1 was observed before and after treatment. Results Before treatment, the level of total cholesterol（TC ）, triglyceride （ TG ）, low density lipoprotein-cholesterol （LDL-C）, high density lipoprotein-cholesterol （HDL-C）,VEGF, NO,TNF-α and IL-1 in two groups had no significant difference （P 〉 0.05 ）. After treatment, the level of TC, TG, LDL-C, TNF- α and IL- 1 in study group were significantly lower than those in control group [ （4.410 ± 0.688 ） mmol/L vs. （6.491 ± 0.744） mmol/L, （ 1.762 ± 0.834） mmol/L vs.（2.632 ± 0.792） mmol/L, （2.256 ± 0.347） mmol/L vs. （4.544 ± 0.493） mmol/L, （41.14 ± 5.41 ） ng/L vs. （71.34 ± 6.76 ） ng/L, （0.22 ± 0.18 ） μg/L vs. （0.42 ± 0.23 ） μg/L ] （P 〈 0.05 ）. The level of HDL-C, VEGF and NO in study group were significantly higer than those in control group [ （ 1.807 ±0.730） mmol/L vs. （ 1.432 ± 0.514） mmol/L, （564.86 ± 120.02） ng/L vs. （451.23 ± 100.72） ng/L, （42.39 ± 6.71 ） μmol/L vs. （33.65 ± 6.24） μmol/L] （P〈 0.05）. No adverse reaαion occurred in two groups. Conclusions Rosuvastatin calcium can obviously decrease the level of lipid, elevate the expression of VEGF and NO, and reduce the expression of TNF- α and IL-1. Rosuvastatin calcium can improve vascular endothelial funαion obviously in hyperlipidemia patients.
出处
《中国医师进修杂志》
2013年第28期26-29,共4页
Chinese Journal of Postgraduates of Medicine
